» Articles » PMID: 38701142

Associations Between Neuroinflammation-Related Conditions and Alzheimer's Disease: A Study of US Insurance Claims Data

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2024 May 3
PMID 38701142
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Early detection of Alzheimer's disease (AD) is a key component for the success of the recently approved lecanemab and aducanumab. Patients with neuroinflammation-related conditions are associated with a higher risk for developing AD.

Objective: Investigate the incidence of AD among patients with neuroinflammation-related conditions including epilepsy, hemorrhage stroke, multiple sclerosis (MS), and traumatic brain injury (TBI).

Methods: We used Optum's de-identified Clinformatics Data Mart Database (CDM). We derived covariate-matched cohorts including patients with neuroinflammation-related conditions and controls without the corresponding condition. The matched cohorts were: 1) patients with epilepsy and controls (N = 67,825 matched pairs); 2) patients with hemorrhage stroke and controls (N = 81,510 matched pairs); 3) patients with MS and controls (N = 9,853 matched pairs); and 4) patients TBI and controls (N = 104,637 matched pairs). We used the Cox model to investigate the associations between neuroinflammation-related conditions and AD.

Results: We identified that epilepsy, hemorrhage stroke, and TBI were associated with increased risks of AD in both males and females (hazard ratios [HRs]≥1.74, p < 0.001), as well as in gender- and race-conscious subpopulations (HRs≥1.64, p < 0.001). We identified that MS was associated with increased risks of AD in both males and females (HRs≥1.47, p≤0.004), while gender- and race-conscious subgroup analysis shown mixed associations.

Conclusions: Patients with epilepsy, hemorrhage stroke, MS, and/or TBI are associated with a higher risk of developing AD. More attention on cognitive status should be given to older patients with these conditions.

References
1.
Musella A, Gentile A, Rizzo F, Vito F, Fresegna D, Bullitta S . Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions. Front Aging Neurosci. 2018; 10:238. PMC: 6092506. DOI: 10.3389/fnagi.2018.00238. View

2.
Tang R, Lin Y, Liu H, Wang E . Neuroprotective effect of docosahexaenoic acid in rat traumatic brain injury model via regulation of TLR4/NF-Kappa B signaling pathway. Int J Biochem Cell Biol. 2018; 99:64-71. DOI: 10.1016/j.biocel.2018.03.017. View

3.
Uekawa K, Hasegawa Y, Ma M, Nakagawa T, Katayama T, Sueta D . Rosuvastatin ameliorates early brain injury after subarachnoid hemorrhage via suppression of superoxide formation and nuclear factor-kappa B activation in rats. J Stroke Cerebrovasc Dis. 2014; 23(6):1429-39. DOI: 10.1016/j.jstrokecerebrovasdis.2013.12.004. View

4.
Kamal H, Tan G, Ibrahim S, Shaikh M, Naina Mohamed I, Mohamed R . Alcohol Use Disorder, Neurodegeneration, Alzheimer's and Parkinson's Disease: Interplay Between Oxidative Stress, Neuroimmune Response and Excitotoxicity. Front Cell Neurosci. 2020; 14:282. PMC: 7488355. DOI: 10.3389/fncel.2020.00282. View

5.
Cummings J, Aisen P, Apostolova L, Atri A, Salloway S, Weiner M . Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2021; 8(4):398-410. PMC: 8835345. DOI: 10.14283/jpad.2021.41. View